logo
logo
Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.

NASDAQ•LXRX
CEO: Mr. Brian T. Crum
セクター: Healthcare
業種: Biotechnology
上場日: 2000-04-07
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
連絡先情報
2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, 77381, United States
281-863-3000
www.lexpharma.com
時価総額
$518.06M
PER (TTM)
-6.9
34.3
配当利回り
--
52週高値
$1.83
52週安値
$0.28
52週レンジ
66%
順位58Top 85.6%
2.3
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$14.18M+710.40%
直近4四半期の推移

EPS

-$0.04-77.78%
直近4四半期の推移

フリーCF

$0.00-100.00%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Licensing Revenue Spike Licensing revenue reached $40.7M for nine months ended September 30, 2025, primarily from Novo Nordisk agreement recognition.
Net Loss Significantly Reduced Nine months net loss narrowed to $(34.8M) versus $(166.6M) reported in the prior year period.
Strong Liquidity Position Total cash and short-term investments stood at $144.950M as of September 30, 2025, supporting operations.
Operating Expense Control Nine months SG&A expenses dropped 74% to $28.6M following late 2024 restructuring actions.

リスク要因

R&D Success Dependency Business heavily relies on successful drug program completion; failure risks significant stock price decline.
Regulatory Approval Uncertainty Drug candidates face lengthy, uncertain regulatory processes potentially limiting or preventing commercialization approvals.
Substantial Indebtedness Limits Existing substantial indebtedness may limit available cash flow needed for ongoing business investment requirements.
Future Capital Needs Additional capital required for Phase 3 development; unavailability forces program delays or scope reduction.

見通し

Pipeline Advancement Focus Expect continued substantial capital devotion to research and development for advancing current drug candidates.
Sufficient 12-Month Runway Current unrestricted cash and expected collaboration revenues fund planned operations for at least 12 months.
Debt Covenant Compliance Company confirmed full compliance with all financial covenants under the Oxford Term Loans as of September 30, 2025.
Stock Sales Flexibility $75M Open Market Sale Agreement capacity remains fully available for potential future equity financing needs.

同業比較

売上高 (TTM)

REGENXBIO Inc.RGNX
$161.32M
+91.3%
ADC Therapeutics SAADCT
$75.21M
+6.4%
Lexicon Pharmaceuticals, Inc.LXRX
$70.86M
+1255.2%

粗利益率 (最新四半期)

Ocugen, Inc.OCGN
100.0%
+0.0pp
Bicycle Therapeutics plcBCYC
100.0%
+1705.8pp
Gossamer Bio, Inc.GOSS
100.0%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
CRVS$1.56B-102.5-25.8%1.3%
RAPT$954.54M-14.7-61.8%1.6%
CMPX$868.44M-13.2-48.9%4.3%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-18.9%
成長鈍化
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
25%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月5日
|
EPS:-$0.07
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $14.18M+710.4%
    |
    EPS: $-0.04-77.8%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月6日|
    売上高: $28.87M+1652.6%
    |
    EPS: $0.01-105.3%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月14日|
    売上高: $1.26M+11.7%
    |
    EPS: $-0.07-65.0%
    予想通り

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月7日|
    売上高: $31.08M+2481.5%
    |
    EPS: $-0.63+21.3%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月13日|
    売上高: $1.75M+980.2%
    |
    EPS: $-0.18-14.3%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月2日|
    売上高: $1.65M+419.6%
    |
    EPS: $-0.17-22.7%
    予想通り

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月2日|
    売上高: $1.13M+4608.3%
    |
    EPS: $-0.20+25.0%
    予想を下回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月25日|
    売上高: $1.20M+766.2%
    |
    EPS: $-0.80-29.0%
    予想を下回る